ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学位論文
  2. 博士論文(医学)
  3. 本文

Mesalazine granule formulation improves clinical data in Crohn’s disease compared with tablet formulation

http://hdl.handle.net/10271/00003871
http://hdl.handle.net/10271/00003871
9543b862-2bcd-4fa9-afc8-180739e03a89
名前 / ファイル ライセンス アクション
DT_862ronbun.pdf 論文本文 (940.5 kB)
license.icon
Item type 学位論文 / Thesis or Dissertation(1)
公開日 2021-08-01
タイトル
タイトル Mesalazine granule formulation improves clinical data in Crohn’s disease compared with tablet formulation
言語 en
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_db06
資源タイプ doctoral thesis
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
その他のタイトル
その他のタイトル メサラジン顆粒剤は錠剤と比較してクローン病の臨床データを改善させる
著者 田村, 智

× 田村, 智

ja 田村, 智

Search repository
書誌情報 en : Scientific Reports

巻 10, p. 21353, 発行日 2020-12-07
出版者
出版者 Springer Nature
言語 en
権利
言語 en
権利情報 Copyright The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
抄録
内容記述タイプ Abstract
内容記述 The efficacy of sustained-release preparations of mesalazine as a remission maintenance treatment for Crohn’s disease remains to be established. We aimed to examine the changes in compliance rate and clinical data 2 years after switching from mesalazine tablet to granule formulation at our facility among patients with Crohn’s disease in remission. We investigated the rate of continuous treatment of mesalazine granules and examined the changes in Crohn’s Disease Activity Index (CDAI) and serum C-reactive protein (CRP), albumin, and hemoglobin (Hb) levels 2 years after the switch. Compliance rate (continuous treatment vs. additional treatment) and continuous treatment rate [good (rate of ≥70%) vs. poor (rate<70%)] were investigated. Of 46 patients, 12 (27.3%) received additional treatment and 32 (72.7%) did not require additional treatment in 2 years. No significant change in CDAI after switching to granule modification was noted in 32 patients in the continuous treatment group. Nevertheless, clinical remission was maintained for 2 years, and serum CRP levels decreased significantly (P=0.023) and Hb levels increased significantly (P=0.002). No change in the compliance rate was found. Our results suggest that mesalazine granule formulation may have a remission maintenance effect that is superior to that of mesalazine tablets.
言語 en
学位名
学位名 博士(医学)
学位の区分
内容記述 doctoral
学位の分野
内容記述 医学系研究科
学位授与機関
学位授与機関識別子Scheme kakenhi
学位授与機関識別子 13802
学位授与機関名 浜松医科大学
学位授与年月日
学位授与年月日 2021-03-16
学位授与番号
学位授与番号 甲第862号
ISSN
収録物識別子タイプ PISSN
収録物識別子 2045-2322
PubMed番号
識別子タイプ PMID
関連識別子 33288852
出版社DOI
識別子タイプ DOI
関連識別子 https://doi.org/10.1038/s41598-020-78603-9
著者版フラグ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-20 16:26:12.260937
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3